Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
33.3M
-
Shares change
-
-224K
-
Total reported value, excl. options
-
$1.82B
-
Value change
-
-$28M
-
Put/Call ratio
-
0.42
-
Number of buys
-
56
-
Number of sells
-
-34
-
Price
-
$54.68
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2021
117 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q2 2021.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.3M shares
of 53.1M outstanding shares and own 62.73% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), Vivo Capital, LLC (4.22M shares), Logos Global Management LP (3.16M shares), WELLINGTON MANAGEMENT GROUP LLP (2.9M shares), VANGUARD GROUP INC (1.55M shares), FMR LLC (1.26M shares), BlackRock Inc. (1.25M shares), JANUS HENDERSON GROUP PLC (1.22M shares), STATE STREET CORP (1.05M shares), and Redmile Group, LLC (914K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.